|Bid||10.81 x 800|
|Ask||11.50 x 1800|
|Day's Range||11.00 - 11.41|
|52 Week Range||6.81 - 17.39|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 5, 2020 - Feb 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.75|
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors need to pay close attention to AMAG Pharmaceuticals (AMAG) stock based on the movements in the options market lately.
The number of pharmaceutical and biotechnology companies seeking Chapter 11 protection has nearly tripled the 10-year average in 2019 and is expected to continue to rise Continue reading...
NEW YORK, NY / ACCESSWIRE / November 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ:AMAG). Such ...
Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. (“AMAG” or the “Company”) (NASDAQ: AMAG). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether AMAG and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
WALTHAM, Mass., Nov. 13, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:.
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -37.25% and -5.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Commercial products achieve strong revenue and market share performance Vyleesi™ (bremelanotide injection) launched nationally in September Committed to work with the FDA to.
NEW YORK, NY / ACCESSWIRE / October 31, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") ...
Shares of Amag Pharmaceuticals collapsed Wednesday after a split Food and Drug Administration advisory committee voted 9-7 to pull its preterm birth prevention drug, Makena, from the market.
AMAG said the FDA's Bone and Reproductive and Urologic Advisory Committee, which met to discuss the PROLONG confirmatory trial for its Makena, voted 9-7 in favor of pulling the product out of the market. Makena is hydroxyprogesterone caproate injection approved in 2011 to reduce preterm birth in pregnant women who have had a prior spontaneous preterm birth.
AMAG Pharmaceuticals, Inc. (AMAG) today announced the U.S. Food and Drug Administration’s (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee met to better understand and interpret the PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) confirmatory clinical trial for Makena® (hydroxyprogesterone caproate injection), a treatment approved to reduce preterm birth in pregnant women who have had a prior spontaneous preterm birth. While the committee discussed multiple questions, in a mixed vote on the key question, nine advisory committee members voted to recommend that the FDA pursue withdrawal of approval for Makena and seven committee members voted to leave the product on the market under accelerated approval and require a new confirmatory trial.
In a surprising move, an FDA advisory committee has recommended that the agency pull Amag Pharmaceuticals' cornerstone product and only approved drug designed to stop pre-term birth off of the market.